

	Agenda		
Tuesday,	17 October 2023		
09:00	Welcome: Opening Remarks & Introduction		Falk Klar, PDA Europe  Theresa Bankston, BD Alessandro Morandotti, Stevanato Group
09:15-12:40 I O Centric Care	pening Plenary: The Evolving Landscape of Patient-	Moderator:	Theresa Bankston, BD
improving patie drivers and enal perspectives fro commercialize, healthcare ecos learned, future	inces in injectable drug delivery have been made over int experience, health outcomes, and total cost of care is blers for this evolution, challenges faced, the impact achies on a patient, drug manufacturer, device developer, as and manage effective therapies, together. The audiencystem dynamics, the role and future of smart devices, hopportunities, and more.	s expected to co eved, and expect nd service provi e can expect to	ontinue. This session will reflect on tations for the future. We will learn ider on what it takes to develop, hear highlights about market and
KEYNOTE PRESI	ENTATIONS		
	The Inspiring Evolution of Parenteral Combination Pro 2004 to Today from an Entrepreneurial Perspective – A What Is Coming		Stephen Perry, Kymanox
	How Understanding Patient Behavior and Experience of the Development and Optimization of Treatments – A Perspective		Piet Christiaens, Nelson Lab
10:15	Coffee Break, Poster Session & Exhibition, Tech Talks & Guided Poster Walk (Part I)		
	How Smart Devices are Impacting Delivery of Care and Patient Experience	l Improving	Ralph Camardelli, Sanofi Eric Dessertenne, Biocorp
	Interactive Questionnaire Session		Via Mentimeter
	Panel Discussion		
12:40	Lunch Break, Poster Session & Exhibition & Tech Talks		
	Transition to Parallel Tra	ncks	



Session 1	Track A	Track B	Track C
14:10-15:30	Large Volume	Digital Health and Smart Devices	Manufacturing
Moderators:	Frank Bamberg, CSL Behring	Jakob Lange, Ypsomed	Laurent Jeanmart, GSK Vaccines
	Large-volume injections are a challenge primarily for the patient. Device manufacturers and the pharmaceutical industry have taken on this challenge. Devices were adapted to the needs of the patients and the injection volume. Additives were developed so that the human body absorbs larger amounts better. In this event, solutions, and the ways to get there will be shown and discussed.	The digital revolution is making its way into the injection device area. This session will provide examples of recent innovations and approaches to include behavioral science in the development of smart devices, how digital health can enable improved adherence tracking, and obtaining regulatory clearance for digital solutions in the injection space.	Regarding manufacturing processes in constant evolution, this session will describe several case studies about track and trace solutions (RFID) and efficient collaboration for stability improvement for a combination product.  Moreover, new Ready to Use (RTU) container aseptic practices in compliance with EU GMP Annex 1 will also be presented.
	Pre-Clinical Assessment of a High-Volume, High-Speed Prototype Auto-Injector to Subcutaneously Deliver a Polyclonal Antibody with Recombinant Human Hyaluronidase PH20 (rHuPH20)  David Kang,	Next Generation Auto-Injectors: Leveraging the Power of a Digital Platform for Enhanced Adherence Tracking  Teodora Caragea,	A Case Study in the Implementation of Radio Frequency Identification (RFID) - Enabled Pre-Filled Syringes on an Aseptic Fill and Finish Line  Herve Soukiassian, BD
	Exploring US Payer Perspectives on Large-Volume Subcutaneous OnBody Delivery Systems: A Double-Blinded Preference Study	Merck KGaA Injecting Behavioral Science into Self-Administration Combination Products, Where Digital Meets Physical: Reflections, Challenges, and Observations	Mario Schwab, Optima  Validatable Transfer Method for Ready to Use (RTU) Syringes and Vials into Grade A in Compliance with EU GMP Annex 1 including a Case Study
	Mehul Desai, Enable Injections	Julian Dixon, AstraZeneca	Andreas Kerschbaumer, <i>Novartis</i> Manfred Holzer, <i>SKAN</i>



	A Case Study: How Stakeholder Needs Guided the Collaborative Development of a Pre-Filled Syringe and an Autoinjector for Large-Volume Subcutaneous Drug Delivery  Sven Pohle, SCHOTT Pharma Reto Jost, Ypsomed	Regulatory Clearance for Implementation of a Digital Solution Supporting Use of an Autoinjector  Christoph Joosten, F. Hoffmann-La-Roche	Synergistic Collaboration with Glass Syringe Manufacturer during Drug Product Lifecycle: A Case Study on Improved Stability for a Combination Product  Stefano Pilati, Stevanato Group Andy Han, Bayer (remote presentation)
	Q&A, Discussion	Q&A, Discussion	Q&A, Discussion
15:30	Coffee Break, Poster Session & E	xhibition + Guided Poster Walk (Pa	art II) & Tech Talks
		Transition to Parallel Tracks	
		Parallel Tracks ABC	
Session 2	Track A	Track B	Track C
16:30-17:50	Patient Interface	Development	Regulatory
Moderators:	Christin Helbig, SCHOTT Pharma  The pharma industry has increasingly adopted the mantra of "patient-centricity" which aims to put the patient at the heart of the consideration of the drug and device development process. In this session, we will present and discuss aspects of Human Factor practices in the context of Low-to-Middle-Income healthcare settings, early inclusive design approaches as well as patient insights on their sustainability expectations of drug delivery devices.	Persistent innovation continues to drive evolution of treatment modalities and injection systems that strive to fulfil growing trends such as novel formulations, self-administration, less frequent dosing, etc. This session will focus on developing robust, reliable, and high-quality drug delivery devices and drug/device combination products. The speakers will discuss approaches to achieve highly desired and equally challenging traits – speed, optimal quality, and enhanced user experience – during the development of combination products through risk-based approach and control strategies.	Manfred Maeder, Novartis  During our regulatory session, we will hear about the most recent changes and expectations on the Medical Device Regulation (MDR) including the expectations on the GSPRs (General Safety and Performance Requirements) for medical devices and drug-device combinations.  And we will learn more about the notified body opinion process and some case studies associated with that new requirement. Furthermore, there will be some evaluation and comparison of new HFE (Human Factors Engineering) requirements around the globe.



	Inclusive Design in Medicine	<b>Combination Products Control</b>	Update on Technical Report 73-2:
	and Device Development	Strategy- A Holistic Approach	Application of Medical Device
		and Statistical Considerations	Regulations, EU GMP Annex I
			Requirements (GSPRs) for Staked
			Needle Syringes
	Dave Pearce and	Ying Wang,	Bettine Boltres,
	Chiko Ncube, GSK	Pfizer	West
	Patient Voices in Sustainable	The Strategy of Accelerating	Article 117 Medical Device
	Drug Delivery: Insights on Self-	Injectable Combination Product	Regulation (MDR) - Notified Body
	Injection Devices	<b>Development for Faster Clinical</b>	Opinion: State of the Play and
		Entry and Market Access	Lessons Learned
	Jakob Lange,	Peng Li,	Christiana Hofmann,
	Ypsomed	Merck Group	Anteris Medical
	Global Health: Deploying	<b>Current Trends and Future</b>	Are we Two of a Kind? Recent
	<b>Human Factors Research</b>	Innovations in Autoinjectors for	Regulatory Developments across
	Within Low-to-Middle-Income	Large-Volume Subcutaneous	the Globe, and how those might
	Countries	Delivery: A Systematic	Impact Future European Human
		Literature Review	Factors Engineering Submissions
	Alejandra Anderson & Timothy		
	Quigg,	Andreas Schneider,	Petra Boeree,
	Crux Product Design	Ypsomed	Emergo by UL
		,	,
17:50	End of Day 1 & Networking Even	it	

Wednesday, 18 October 2023				
09:00-10:20   Morning Plenary: Industry Partnerships for Sustainable Product Design and Recycling  Moderator: Akshay R. Kamdar, Eli Lilly and Company				
This plenary session focuses on the importance of sustainability in the pharma/biotech industry. Key topics such as designing products with a patient and planet-centric mindset, addressing recycling challenges for medical devices with design guidance for end-of-life recycling, and exploring industry partnerships and collaborations for recycling will be highlighted.				
KEYNOTE PRESENTATIONS				
	Designing for Patients and the Planet: Circular Solution Pharmaceutical Products	s for	Cedric Gysel, Johnson & Johnson	
	Industry Collaboration for Device Sustainability		Paolo Mangiagalli, Sanofi	
	HPRC Design Guidance: Enabling Recycling at End-of-Li	fe	Bas Coolsma, Healthcare Plastics Recycling Council (HPRC)	



	Addressing Recycling: One of the Bottlenecks of Circularity		Naresh Budhavaram, Eli Lilly and Company	
	Panel Discussion			
10:20	Coffee Break, Poster Session & Exhibition & Tech Talks			
		Parallel Tracks ABC		
Session 3	Track A Track B Track C			
11:05-12:25	Sustainability	Innovation and Collaboration	Drug Container Interaction	
Moderators:	Marion Briggs, HealthBeacon on behalf of Alliance to Zero	Philippe Lauwers, Terumo	Roman Mathaes, Clear Solutions	
	This session will focus on the primary drivers and challenges when considering sustainable models within the industry. Our speakers will cover the critical factors influencing lifecycle assessments, digital solutions within sustainability, and how to leverage these processes to increase operational efficiency. Key highlights include real-world examples, strategies for implementation, and how to	Speed to market has become a differentiating factor for success in the pharma industry nowadays. To bring products to market quickly, pharma companies, device suppliers, and contract manufacturers must build strong and efficient partnerships and establish robust supply chain channels. In this session, we will provide valuable insights from all stakeholders and offer recommendations on how to accelerate development, foster seamless collaboration, and better meet customer needs.	our session will focus on the unique challenges encountered in developing pre-filled syringes for intravitreal injections.	
	Carbon Footprint of Capital Good Gains Attention	From Drug Development to Final- Packaged Product: The Role of Strategic Partnerships in Streamlining On-Body Delivery Systems Manufacturing	Silicone Depletion in Combination Products Induced by Biologics	
	Markus Winter, Harro Höfliger Bernhard Gerl, Körber Pharma	Christian Riva, Stevanato Group Chris Howell, ThermoFisher	Wolfgang Friess, Ludwig- Maximilians-Universität München	



i e	Francisco Comiti di	lana antana and CO I at				
	EcoDesign Considerations and	-			Comprehensive Countermeasures	
	CO <sup>2</sup> Reduction for Medical				educe Proteinaceous Visible	
	Devices	Partnerships for Combin			cicles in Liquid Monoclonal	
		Product Development a		Anti	body Products	
		Lifecycle Management -	•			
		Perspectives from a				
		Pharmaceutical Compar	iy and A			
		Device Manufacturer				
	Glenn Svedberg,	Tushar Patki, Biogen (rer	note	Keiii	ro Hatade,	
	Nolato AB	presentation)		,	gai Pharmaceutical	
		Nathan Kast, BD		· ·		
	A Parametric Model	The Secret of Successful		Deli	vering a Superior Ophthalmic	
	Developed from Activity-	Partnerships between		Pre-	Filled Syringe (PFS) with Low	
	<b>Based Footprinting to Simplify</b>	Pharmaceutical Compar	ies and	Part	icles and Exceptional Human	
	the Complexity of Lifecycle	Their Device Suppliers		Fact	ors	
	<b>Assessment Towards</b>					
	Sustainable Autoinjector					
	Devices					
	V			<b>.</b>	W 'I + 6102	
	Veluska Bruce, SHL Medical	Jiaying Shen,			s Weikart, SIO2	
	SHL Wedical	Merck & Co, Inc		31111	on Lay, <i>Cytiva</i>	
	Q&A, Discussion	Q&A, Discussion		Q&/	A, Discussion	
Ì						
42.25						
12:25	Lunch Break, Poster Session & E	xhibition & Tech Talks				
12:25	Lunch Break, Poster Session & E	xhibition & Tech Talks				
	Lunch Break, Poster Session & E  Closing Plenary - Keynotes	exhibition & Tech Talks	Moderato	r:	Alessandro Morandotti,	
14:25-17:15 I	Closing Plenary - Keynotes				Stevanato Group	
14:25-17:15 I C	Closing Plenary - Keynotes  Impliance is key for the successful  Idea of the regulatory strategy. In	ıl development of combii this session, we will revie	nation prod w and discu	lucts.	Stevanato Group  Fulfilling these requisites imply a implication of the New EU GMP	
14:25-17:15 I Continues upd Annex 1 on th	Closing Plenary - Keynotes  Impliance is key for the successful  Idea of the regulatory strategy. In  Interpre-filled syringes manufacturing	Il development of combine this session, we will review and processing, and we	nation prod w and discu	lucts.	Stevanato Group  Fulfilling these requisites imply a implication of the New EU GMP	
14:25-17:15 I Continues upd Annex 1 on th	Closing Plenary - Keynotes  Impliance is key for the successful lated of the regulatory strategy. In the pre-filled syringes manufacturin to have a look at what is coming in	Il development of combine this session, we will review and processing, and we next.	nation proc w and discu will conclu	lucts.	Stevanato Group Fulfilling these requisites imply a implication of the New EU GMP ith an overview of the emerging	
14:25-17:15 I Continues upd Annex 1 on th	Closing Plenary - Keynotes  Impliance is key for the successful ated of the regulatory strategy. In the pre-filled syringes manufacturing to have a look at what is coming in  Manufacturing of Pre-Filled Syringes	Il development of combine this session, we will review and processing, and we next.	nation proc w and discu will conclu	lucts.	Stevanato Group  Fulfilling these requisites imply a implication of the New EU GMP ith an overview of the emerging  Daniel Müller, Local	
14:25-17:15 I Continues upd Annex 1 on th	Closing Plenary - Keynotes  Impliance is key for the successful lated of the regulatory strategy. In the pre-filled syringes manufacturin to have a look at what is coming in	Il development of combine this session, we will review and processing, and we next.	nation proc w and discu will conclu	lucts.	Stevanato Group Fulfilling these requisites imply a implication of the New EU GMP ith an overview of the emerging	
14:25-17:15 I Continues upd Annex 1 on th	Closing Plenary - Keynotes  Impliance is key for the successful lated of the regulatory strategy. In the pre-filled syringes manufacturin to have a look at what is coming in Manufacturing of Pre-Filled Syringes Annex 1  Global Regulatory Policies Impa	ul development of combine this session, we will review and processing, and we next.  Inges – The Impact of New inges – The	nation prod w and discu w will conclu	lucts. Iss the	Stevanato Group  Fulfilling these requisites imply implication of the New EU GMP ith an overview of the emerging  Daniel Müller, Local Inspectorate Tübingen  Rumi Young, BD (Former FDA-	
14:25-17:15 I Continues upd Annex 1 on th	Closing Plenary - Keynotes  Impliance is key for the successful lated of the regulatory strategy. In the pre-filled syringes manufacturin to have a look at what is coming in  Manufacturing of Pre-Filled Syringes  Annex 1	ul development of combine this session, we will review and processing, and we next.  Inges – The Impact of New inges – The	nation prod w and discu w will conclu	lucts. Iss the	Stevanato Group  Fulfilling these requisites imply implication of the New EU GMP ith an overview of the emerging  Daniel Müller, Local Inspectorate Tübingen	
14:25-17:15 I Continues upd Annex 1 on the global policies	Closing Plenary - Keynotes  Impliance is key for the successful ated of the regulatory strategy. In the pre-filled syringes manufacturin to have a look at what is coming to Manufacturing of Pre-Filled Syri Annex 1  Global Regulatory Policies Impa Devices	il development of combination this session, we will review and processing, and we next.  Inges – The Impact of New acting Prefilled Syringes and processing are setting Prefilled Syringes and prefilled Syrin	nation prod w and discu w will conclu	lucts. Iss the	Stevanato Group  Fulfilling these requisites imply implication of the New EU GMP ith an overview of the emerging  Daniel Müller, Local Inspectorate Tübingen  Rumi Young, BD (Former FDA-	
14:25-17:15 I Continues upd Annex 1 on th	Closing Plenary - Keynotes  Impliance is key for the successful lated of the regulatory strategy. In the pre-filled syringes manufacturin to have a look at what is coming in Manufacturing of Pre-Filled Syringes Annex 1  Global Regulatory Policies Impa	il development of combination this session, we will review and processing, and we next.  Inges – The Impact of New acting Prefilled Syringes and processing are setting Prefilled Syringes and prefilled Syrin	nation prod w and discu w will conclu	lucts. Iss the	Stevanato Group  Fulfilling these requisites imply implication of the New EU GMP ith an overview of the emerging  Daniel Müller, Local Inspectorate Tübingen  Rumi Young, BD (Former FDA-	
14:25-17:15 I Continues upd Annex 1 on the global policies	Closing Plenary - Keynotes  Impliance is key for the successful ated of the regulatory strategy. In the pre-filled syringes manufacturin to have a look at what is coming to Manufacturing of Pre-Filled Syri Annex 1  Global Regulatory Policies Impa Devices	il development of combination this session, we will review and processing, and we next.  Inges – The Impact of New acting Prefilled Syringes and processing are setting Prefilled Syringes and prefilled Syrin	nation prod w and discu w will conclu	lucts. Iss the	Stevanato Group  Fulfilling these requisites imply implication of the New EU GMP ith an overview of the emerging  Daniel Müller, Local Inspectorate Tübingen  Rumi Young, BD (Former FDA-	
14:25-17:15 I or Regulatory Co continues upd Annex 1 on the global policies 15:15	Closing Plenary - Keynotes  Impliance is key for the successful lated of the regulatory strategy. In the pre-filled syringes manufacturing to have a look at what is coming to have a look at which have a look at wh	il development of combination this session, we will review and processing, and we next.  Inges – The Impact of New acting Prefilled Syringes and processing are setting Prefilled Syringes and prefilled Syrin	nation prod w and discu w will conclu	lucts. Iss the	Stevanato Group  Fulfilling these requisites imply implication of the New EU GMP ith an overview of the emerging  Daniel Müller, Local Inspectorate Tübingen  Rumi Young, BD (Former FDA-	
14:25-17:15 I CREGULATORY CO CONTINUES UPOLATORY 1 ON the global policies	Closing Plenary - Keynotes  Impliance is key for the successful ated of the regulatory strategy. In the pre-filled syringes manufacturin to have a look at what is coming to Manufacturing of Pre-Filled Syri Annex 1  Global Regulatory Policies Impa Devices	il development of combination this session, we will review and processing, and we next.  Inges – The Impact of New acting Prefilled Syringes and processing are setting Prefilled Syringes and prefilled Syrin	nation prod w and discu w will conclu	lucts. Iss the	Stevanato Group  Fulfilling these requisites imply implication of the New EU GMP ith an overview of the emerging  Daniel Müller, Local Inspectorate Tübingen  Rumi Young, BD (Former FDA-	



	Closing Panel Discussion	
	Join our Discussion with Experts from the Industry ar	nd Regulatory
	Bart Burgess, SHL Medical	
	Stephen Fournier, CSL Behring	
	Manfred Maeder, Novartis	
	Daniel Müller, Local Inspectorate Tübingen	
	Karthik Vaideeswaran, Eli Lilly and Company	,
	Rumi Young, BD (Former FDA-Regulator)	
	Co-Chairs Conference Summary	Theresa Bankston, <i>BD</i> Alessandro Morandotti, <i>Stevanato Group</i>
	Closing Comments & Farewell	Falk Klar, PDA Europe
17:15	End of Conference	•